LADAR

KBRA Assigns Preliminary Ratings to LAD Auto Receivables Trust 2024-1

Retrieved on: 
Thursday, February 1, 2024

KBRA assigns preliminary ratings to four classes of notes (seven tranches) issued by LAD Auto Receivables Trust 2024-1 ("LADAR 2024-1"), an auto loan ABS transaction.

Key Points: 
  • KBRA assigns preliminary ratings to four classes of notes (seven tranches) issued by LAD Auto Receivables Trust 2024-1 ("LADAR 2024-1"), an auto loan ABS transaction.
  • LADAR 2024-1 represents the seventh overall ABS securitization for Driveway Finance Corporation ("DFC" or the "Company"), and first of 2024.
  • DFC is a wholly owned subsidiary of Lithia Financial Corporation, itself a wholly owned subsidiary of Lithia Motors, Inc. (“Lithia”).
  • KBRA considered its operational review of Lithia and DFC, as well as several business updates with the Company since that time.

KBRA Assigns Preliminary Ratings to LAD Auto Receivables Trust 2023-4

Retrieved on: 
Thursday, November 2, 2023

KBRA assigns preliminary ratings to four classes of notes (seven tranches) issued by LAD Auto Receivables Trust 2023-4 (“LADAR 2023-4”), an auto loan ABS transaction.

Key Points: 
  • KBRA assigns preliminary ratings to four classes of notes (seven tranches) issued by LAD Auto Receivables Trust 2023-4 (“LADAR 2023-4”), an auto loan ABS transaction.
  • LADAR 2023-4 represents the sixth overall ABS securitization for Driveway Finance Corporation (“DFC” or the “Company”), and fourth of 2023.
  • DFC is a wholly owned subsidiary of Lithia Financial Corporation, itself a wholly owned subsidiary of Lithia Motors, Inc. (“Lithia”).
  • KBRA considered its onsite operational review of Lithia and DFC at its Tigard, OR location, as well as periodic due diligence updates with Lithia and DFC.

KBRA Assigns Ratings to LAD Auto Receivables Trust 2023-3

Retrieved on: 
Wednesday, August 23, 2023

KBRA assigns ratings to seven classes of notes issued by LAD Auto Receivables Trust 2023-3 (“LADAR 2023-3”), an auto loan ABS transaction.

Key Points: 
  • KBRA assigns ratings to seven classes of notes issued by LAD Auto Receivables Trust 2023-3 (“LADAR 2023-3”), an auto loan ABS transaction.
  • LADAR 2023-3 represents the fifth overall ABS securitization for Driveway Finance Corporation (“DFC” or the “Company”), and third of 2023.
  • DFC is a wholly owned subsidiary of Lithia Financial Corporation, itself a wholly owned subsidiary of Lithia Motors, Inc. (“Lithia”).
  • KBRA considered its onsite operational review of Lithia and DFC at its Tigard, OR location, as well as periodic due diligence updates with Lithia and DFC.

KBRA Assigns Preliminary Ratings to LAD Auto Receivables Trust 2023-3

Retrieved on: 
Thursday, August 10, 2023

KBRA assigns preliminary ratings to seven classes of notes issued by LAD Auto Receivables Trust 2023-3 (“LADAR 2023-3”), an auto loan ABS transaction.

Key Points: 
  • KBRA assigns preliminary ratings to seven classes of notes issued by LAD Auto Receivables Trust 2023-3 (“LADAR 2023-3”), an auto loan ABS transaction.
  • LADAR 2023-3 represents the fifth overall ABS securitization for Driveway Finance Corporation (“DFC” or the “Company”), and third of 2023.
  • DFC is a wholly owned subsidiary of Lithia Financial Corporation, itself a wholly owned subsidiary of Lithia Motors, Inc. (“Lithia”).
  • KBRA considered its onsite operational review of Lithia and DFC at its Tigard, OR location, as well as periodic due diligence updates with Lithia and DFC.

KBRA Assigns Preliminary Ratings to LAD Auto Receivables Trust 2023-2

Retrieved on: 
Wednesday, May 10, 2023

KBRA assigns preliminary ratings to six classes of notes issued by LAD Auto Receivables Trust 2023-2 (“LADAR 2023-2”), an auto loan ABS transaction.

Key Points: 
  • KBRA assigns preliminary ratings to six classes of notes issued by LAD Auto Receivables Trust 2023-2 (“LADAR 2023-2”), an auto loan ABS transaction.
  • LADAR 2023-2 represents the second term ABS securitization for Driveway Finance Corporation (“DFC” or the “Company”) in 2023 and the fourth overall.
  • DFC is a wholly owned subsidiary of Lithia Financial Corporation, itself a wholly owned subsidiary of Lithia Motors, Inc. (“Lithia”).
  • KBRA considered its onsite operational review of Lithia and DFC at its Tigard, OR location, as well as periodic due diligence updates with Lithia and DFC.

KBRA Assigns Preliminary Ratings to LAD Auto Receivables Trust 2023-1

Retrieved on: 
Friday, February 3, 2023

KBRA assigns preliminary ratings to six classes of notes issued by LAD Auto Receivables Trust 2023-1 (“LADAR 2023-1”), an auto loan ABS transaction.

Key Points: 
  • KBRA assigns preliminary ratings to six classes of notes issued by LAD Auto Receivables Trust 2023-1 (“LADAR 2023-1”), an auto loan ABS transaction.
  • This transaction is the third ABS securitization for Driveway Finance Corporation (“DFC” or the “Company”).
  • DFC’s first two ABS securitizations, LADAR 2022-1 and LADAR 2023-1, were both rated by KBRA.
  • DFC is a wholly owned subsidiary of Lithia Financial Corporation, itself a wholly owned subsidiary of Lithia Motors, Inc. (“Lithia”).

KBRA Assigns Preliminary Ratings to LAD Auto Receivables Trust 2022-1

Retrieved on: 
Friday, August 5, 2022

KBRA assigns preliminary ratings to three classes of notes issued by LAD Auto Receivables Trust 2022-1 (LADAR 2022-1), an auto loan ABS transaction.

Key Points: 
  • KBRA assigns preliminary ratings to three classes of notes issued by LAD Auto Receivables Trust 2022-1 (LADAR 2022-1), an auto loan ABS transaction.
  • This transaction is the second ABS securitization for Driveway Finance Corporation (DFC or the Company).
  • DFCs first ABS securitization was LADAR 2021-1, closed on November 12, 2021, and was also rated by KBRA.
  • DFC is a wholly owned subsidiary of Lithia Financial Corporation, itself a wholly owned subsidiary of Lithia Motors, Inc. (Lithia).

CARsgen Appoints Dr. Raffaele Baffa as Chief Medical Officer

Retrieved on: 
Thursday, April 7, 2022

Prior to joining CARsgen, Dr. Baffa served as Chief Medical Officer and Executive Vice President of Research & Development at Ziopharm Oncology (NASDAQ: ZIOP), which was rebranded to Alaunos in January 2022.

Key Points: 
  • Prior to joining CARsgen, Dr. Baffa served as Chief Medical Officer and Executive Vice President of Research & Development at Ziopharm Oncology (NASDAQ: ZIOP), which was rebranded to Alaunos in January 2022.
  • Prior to Ziopharm Oncology, Dr. Baffa was Head of Research & Development and Chief Medical Officer in Medisix Therapeutics, a company focused on developing novel immune cell therapies.
  • Dr. Zonghai Li, Founder, Chairman of the Board, Chief Executive Officer, and Chief Scientific Officer of CARsgen Therapeutics Holdings Limited, said, "We warmly welcome Dr. Baffa to join CARsgen.
  • Dr. Raffaele Baffa, Chief Medical Officer of CARsgen Therapeutics Holdings Limited, said, "I am very excited to join CARsgen.

CARsgen 2021 Annual Results: Steady Advancement in Innovative CAR T Products and Technologies

Retrieved on: 
Wednesday, March 23, 2022

In North America, CARsgen has initiated the Phase 1b trial of CT041-ST-02 and has treated the first subject in July 2021.

Key Points: 
  • In North America, CARsgen has initiated the Phase 1b trial of CT041-ST-02 and has treated the first subject in July 2021.
  • CARsgen strives to explore and develop innovative technology platforms to address these challenges to generate better cell therapy products to global cancer patients.
  • The main focus includes:
    Increasing efficacy against solid tumors: developing innovative technologies, such as CycloCAR technology, to enhance efficacies of CAR T-cell against solid tumors.
  • Improving target availability: exploring innovative technologies that can potentially enhance drug target availability and specificity of CAR T-cell therapy.

SkyWater is Now Accepting Design Submissions for its 90 nm ROIC Multi-Project Wafer Program

Retrieved on: 
Friday, September 3, 2021

SkyWater Technology (NASDAQ: SKYT), the trusted technology realization partner, today announced it is accepting design submissions for its 90 nm readout integrated circuit (S90ROIC) multi-project wafer (MPW) program, which enables quick and low-cost prototyping and design enablement, including support for ITAR designs.

Key Points: 
  • SkyWater Technology (NASDAQ: SKYT), the trusted technology realization partner, today announced it is accepting design submissions for its 90 nm readout integrated circuit (S90ROIC) multi-project wafer (MPW) program, which enables quick and low-cost prototyping and design enablement, including support for ITAR designs.
  • Design submissions for SkyWaters initial enhanced S90ROIC MPW shuttle are now being accepted with a GDS-II cutoff date in November 2021.
  • Volume ROIC manufacturing is available at SkyWaters ISO 9001, ITAR-compliant and DMEA-accredited Trusted U.S. production facility.
  • For more information on how to submit a design or if you have questions regarding SkyWaters ROIC MPW program, please visit: https://www.skywatertechnology.com/mpw/ .